ImmunoGen, a Waltham, Massachuetts-based biopharmaceutical company, has shifted to an operating model that relies on external manufacturing and quality testing for drug substances and drug products for its development programs, resulting in a closure of its manufacturing facility in Norwood, Massachusetts.

Following a review of the company’s manufacturing strategy, ImmunoGen chose to implement the new model. The implementation of the new operating model will lead to the closure of manufacturing and quality activities at the company’s Norwood facility by the end of 2018, with a full exit of the site by early 2019. ImmunoGen says decommissioning the Norwood facility will result in anticipated cost savings of over $20 million during the next five years.

Source: ImmunoGen